Loading clinical trials...

Performance of an Investigational Blood Glucose Monitoring System | Clinical Trials | Clareo Health

COMPLETEDNA

Performance of an Investigational Blood Glucose Monitoring System

Performance of the Ninja 3 Plus Blood Glucose Monitoring System

NCT01824355•Ascensia Diabetes Care

Summary

The purpose of this study was to demonstrate that untrained subjects who have diabetes can operate the Investigational Blood Glucose Monitoring System (BGMS) and obtain valid glucose results.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Males and females, 18 years of age or older.
•2. People with type 1 or type 2 diabetes.
•3. Able to speak, read and understand English.
•4. Willing to complete all study procedures.

Exclusion Criteria

•1. Hemophilia or any other bleeding disorder.
•2. Pregnancy.
•3. Physical, visual or neurological impairments that would make the person unable to perform testing with the BGM.
•4. Previously participated in a blood glucose monitoring study using the Ninja 3 Plus BGMS.
•5. Working for a medical laboratory, hospital or other clinical setting that involves training on or clinical use of blood glucose meters.
•6. Working for a competitive medical device company, or having an immediate family member who works for such a company.
•7. A condition, which in the opinion of the investigator or designee, would put the person or study conduct at risk.

Locations (1)

Consumer Product Testing Co.

Fairfield, New Jersey, United States

Key Dates

Start Date

March 1, 2013

Primary Completion Date

March 1, 2013

Completion Date

March 1, 2013

Last Updated

February 29, 2016

Enrollment

113

ACTUAL participants

Conditions

Diabetes

Interventions

Ninja 3 PLUS Investigational BG Monitoring System

DEVICE

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITING

Genetic Studies of Insulin and Diabetes

NCT00001987

Diabetes MellitusSevere Insulin Resistance

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 29, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Performance of an Investigational Blood Glucose Monitoring System

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Genetic Studies of Insulin and Diabetes

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

iGlarLixi CGM Study in Chinese T2D Individuals After OADs